Research
Our members represent a breadth of experience in hematological malignancies with extramural funding from such prestigious sponsors as the National Institutes of Health, the American Cancer Society and the Society for Leukemia and Lymphoma.
Faculty by Research Area
James O. Armitage, MD: Non-Hodgkin Lymphoma, Hodgkin Disease, Chronic Lymphocytic Leukemia
Javeed Iqbal, PhD: Lymphoma
Julie M. Vose, MD, MBA: Non-Hodgkin Lymphoma, Hodgkin Disease, Multiple Myeloma, Chronic Lymphocytic Leukemia
Vijaya Raj Bhatt, MBBS, MS: Understanding the functional trajectories through the course of leukemia treatment, and improving quality of life and survival of adults with acute leukemias
R. Gregory Bociek, MD: Non-Hodgkin Lymphoma, Hodgkin Disease, Chronic Lymphocytic Leukemia
Matthew Lunning, DO, FACP: Non-Hodgkin Lymphoma, Hodgkin Disease, Multiple Myeloma, CAR-T/Cellular Therapy, Benign Hematology
Sarah Holstein, MD, PhD: Multiple myeloma with an emphasis on the development of novel therapeutic agents
Kate Hyde, PhD: Acute myeloid leukemia
Hamid Band, MD, PhD: Breast cancer and intracellular trafficking
Don Coulter, MD: Pediatric Hematology and Oncology
Krishna Gundabolu, MBBS, MS: Coagulation Disorders & Non-Malignant Hematology
Joseph D. Khoury, MD: Hematopathology, Lymphoma, Leukemia
Hamid Band, MD, PhD: Molecular Control of Tyrosine Kinase Signaling: Cell Biology and translation
Srivatsan Kidambi, PhD: Developing biomimetic models of different tissues (cancer, liver, brain) to understand the role of the tissue microenvironment during aging and disease progression
Xu Luo, PhD: Molecular mechanisms and signaling pathways in cell death and survival in cancer cells
Rakesh K. Singh, PhD: Cancer metastasis; tumor immunology
Yan Ying, PhD: Cell signaling; radiation and chemotherapy resistance
Janina Baranowska-Kortylewicz, PhD, Msc: Design of theranostics for individualized treatment of cancer
Scott Koepsell, MD, PhD: Cellular therapy, molecular diagnostics, proteomics
DJ Murry, PharmD: Dosing strategies for Phase I clinical trials; surrogate endpoints in clinical trials; pharmacokinetics and pharmacogenomics for individualized drug therapy
Amar Natarajan, PhD: Developing novel target and mechanism specific therapeutics
David Oupicky, PhD: Design of multifunctional nanoparticles for the treatment of metastatic cancer and inflammatory conditions
JOACHMR Resources
Clinical database: A key asset of the center is its large, computerized clinical database, which contains detailed pathology and genetic information on lymphoma cases.
Tissue bank: Complementing this is an extensive tissue bank that houses fresh and frozen samples of all hematological malignancies. During the past five years alone, a wide variety of samples and specimens have been collected, including over 800 frozen/fresh tissue samples, isolated cell suspensions, and blood/marrow specimens.These resources are invaluable to the center's mission and serve as a foundation for high-impact research efforts across disciplines.
Publications & Grants
Publications: JOACHMR members have been published well over 1,000 times in the past 10 years.
Grants: Grants and contracts supporting our research in the past five years:
- Lymphoma: 149 funded grants and contracts, with a total cost of over $11 million
- Leukemia: 88 funded grants and contracts, with a total cost of over $8.2 million
- Multiple Myeloma: 64 funded grants and contracts, with a total cost of over $8.8 million
- Pathology, Microbiology, and Immunology: 25 funded grants and contracts, with a total cost of over $6.5 million
Academics
Faculty members represent a broad range of departments and institutes, including Pathology, Hematology/Oncology (adult and pediatric), Anatomy and Cell Biology, Genetics and Cell Biology, Microbiology and Molecular Immunology (MMI) the Eppley Cancer Institute, Nursing, Pharmacology, and the Nebraska Medical Center.
JOACHMR is actively involved in the training of graduate students, postdoctoral fellows, clinical fellows, summer students, and visiting faculty. In addition, many of the members are involved in promoting education through the Lymphoma Research Foundation and Leukemia and Lymphoma Society and participate in the clinical think tank for the Mantle Cell Lymphoma Consortium, and the Follicular Lymphoma Consortium.